The Impact of the Availability of Immunotherapy on Patterns of Care in Stage III NSCLC: A Dutch Multicenter Analysis.

Ronden MI, Bahce I, Claessens NJM, Barlo N, Dahele MR, Daniels JMA, Tissing-Tan C, Hekma E, Hashemi SMS, van der Wel A, Spoelstra FOB, Verbakel WFAR, Tiemessen MA, van Laren M, Becker A, Tarasevych S, Haasbeek CJA, Maassen van den Brink K, Dickhoff C, Senan S

Open source

DOI
10.1016/j.jtocrr.2021.100195
Published
2021 Jul
Container
JTO clinical and research reports
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.jtocrr.2021.100195,
  title = {The Impact of the Availability of Immunotherapy on Patterns of Care in Stage III NSCLC: A Dutch Multicenter Analysis.},
  author = {Ronden MI and Bahce I and Claessens NJM and Barlo N and Dahele MR and Daniels JMA and Tissing-Tan C and Hekma E and Hashemi SMS and van der Wel A and Spoelstra FOB and Verbakel WFAR and Tiemessen MA and van Laren M and Becker A and Tarasevych S and Haasbeek CJA and Maassen van den Brink K and Dickhoff C and Senan S},
  year = {2021},
  journal = {JTO clinical and research reports},
  doi = {10.1016/j.jtocrr.2021.100195},
  url = {https://doi.org/10.1016/j.jtocrr.2021.100195}
}

RIS

TY  - JOUR
TI  - The Impact of the Availability of Immunotherapy on Patterns of Care in Stage III NSCLC: A Dutch Multicenter Analysis.
AU  - Ronden MI
AU  - Bahce I
AU  - Claessens NJM
AU  - Barlo N
AU  - Dahele MR
AU  - Daniels JMA
AU  - Tissing-Tan C
AU  - Hekma E
AU  - Hashemi SMS
AU  - van der Wel A
AU  - Spoelstra FOB
AU  - Verbakel WFAR
AU  - Tiemessen MA
AU  - van Laren M
AU  - Becker A
AU  - Tarasevych S
AU  - Haasbeek CJA
AU  - Maassen van den Brink K
AU  - Dickhoff C
AU  - Senan S
PY  - 2021
JO  - JTO clinical and research reports
DO  - 10.1016/j.jtocrr.2021.100195
UR  - https://doi.org/10.1016/j.jtocrr.2021.100195
ER  - 

APA

MI, R., I, B., NJM, C., N, B., MR, D., JMA, D., C, T., E, H., SMS, H., A, V. D. W., FOB, S., WFAR, V., MA, T., M, V. L., A, B., S, T., CJA, H., K, M. V. D. B., C, D., & S, S. (2021). The Impact of the Availability of Immunotherapy on Patterns of Care in Stage III NSCLC: A Dutch Multicenter Analysis.. JTO clinical and research reports. https://doi.org/10.1016/j.jtocrr.2021.100195

Source records